Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy
Al-Alfy, M., Abd Elkader, A., M.A.A, S., Yasseen, A. (2645). Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy. EKB Journal Management System, 2024(8), -. doi: 10.58675/2682-339X.2561
Mohammed Al-Alfy; Ahmed Abd Elkader; Shaheen M.A.A; Ahmed Yasseen. "Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy". EKB Journal Management System, 2024, 8, 2645, -. doi: 10.58675/2682-339X.2561
Al-Alfy, M., Abd Elkader, A., M.A.A, S., Yasseen, A. (2645). 'Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy', EKB Journal Management System, 2024(8), pp. -. doi: 10.58675/2682-339X.2561
Al-Alfy, M., Abd Elkader, A., M.A.A, S., Yasseen, A. Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy. EKB Journal Management System, 2645; 2024(8): -. doi: 10.58675/2682-339X.2561

Benefits of Levothyroxine Replacement Therapy in Subclinical Hypothyroidism Egyptian Patients with Chronic Hepatic Encephalopathy

Al-Azhar International Medical Journal
Volume 2024, Issue 8, August 2024  XML
DOI: 10.58675/2682-339X.2561
View on SCiNiTO View on SCiNiTO
Authors
Mohammed Al-Alfy1; Ahmed Abd Elkader1; Shaheen M.A.A2; Ahmed Yasseen1
1Internal Medicine, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
2Clinical pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Abstract
Background: Subclinical hypothyroidism (SCH) is a condition marked by increased concentrations of thyroid-stimulating hormone (TSH) in the bloodstream, along with normal thyroxine (T4) and triiodothyronine (T3) concentrations. Aims and objectives: To assess the benefits of levothyroxine replacement treatment in SCH cases with chronic hepatic encephalopathy (HE), Patients and methods: This comparative research was performed on 50 Egyptian cases aged 18–65 with SCH and chronic HE, separated into two groups: Group I: 25 cases did not receiveLT4 replacement therapy, and Group II: 25 patients received LT4 replacement therapy chosen from the outpatient clinic of & admitted to the Internal Medicine department of Sayed Galal Hospital Al-Azhar University from May 2023 to November 2023. Results: Regarding liver function tests following six months, there was a statistically significant variance among Group I and Group II as regards aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Regarding thyroid function tests and lipid profile following six months, there was statistically significant variance among groups I and II with regard to TSH and HE grade and a highly statistically significant distinction with regard to ammonia and triglycerides (TGs). Regarding the Child-Pugh score and hepatic encephalopathy frequency following six months, there was a statistically significant distinction between groups I and II. Conclusion: SCH can trigger HE in cirrhotic individuals, which can lead to hyperammonemia and/or worsen ammonia brain toxicity. Thus, it is important to assess for hypothyroidism in patients with cirrhosis and refractory HE, especially when considering aggressive therapies.
Statistics
Article View: 17